-
摘要: 第19届欧洲克罗恩和结肠炎组织年会的主题是“炎症性肠病中的跨界”。本次会议发布了炎症性肠病新疗法、新策略以及新治疗终点的进展。本届年会在克罗恩病的治疗方法方面突出了新型生物制剂、小分子药物的疗效研究和安全性分析。在克罗恩病的治疗策略方面纳入了更多新理念，炎症生物学标志物与“降阶梯”和“升阶梯”策略、等位基因指导用药、外科手术方式和肛周瘘管癌的筛选策略等为临床治疗的优化提供了新方向。本文对会议关于克罗恩病的新疗法和新策略做一综述，以期为我国克罗恩病的研究方向提供一些新的思路。Abstract: The 19th European Crohn's and Colitis Organisation(ECCO) Annual Congress focused on "Crossing borders in inflammatory bowel disease". The congress unveiled advancements in new therapies, strategies, and treatment endpoints for inflammatory bowel disease. Highlighted at this year's ECCO congress were novel biologic agents, efficacy studies on small molecule drugs, and safety analyses in the treatment of Crohn's disease. The treatment strategies for Crohn's disease incorporated new concepts, including inflammatory biomarkers coupled with "step-up" and "step-down" approaches, pharmacogenomics, surgical methods, and screening strategies for perianal fistula carcinoma, offering fresh perspectives for optimizing clinical treatments. This view discusses the new therapies and strategies presented at the conference, aiming to provide insights into research directions for Crohn's disease in our country.
-
Key words:
- Crohn's disease /
- biologic agents /
- small molecule drugs /
- treatment strategies
-
-
[1] Ferrante M, Danese S, Chen M, et al. Op05 primary efficacy and safety of mirikizumab in moderate to severe crohn's disease: Results of the treat-through vivid 1 study[J]. J Crohns Colitis, 2024, 18: i7-i9. doi: 10.1093/ecco-jcc/jjad212.0005
[2] Vermeire S, Allegretti JR, Kim HJ, et al. Op09 oral ritlecitinib and brepocitinib in patients with moderate to severe active crohn's disease: Data from the pizzicato umbrella study[J]. J Crohns Colitis, 2024, 18: i16. doi: 10.1093/ecco-jcc/jjad212.0009
[3] D'Haens G, Louis E, Loftus Jr EV, et al. Op10 efficacy and safety of upadacitinib in patients with moderately to severely active crohn's disease: Results from the u-endure long-term extension[J]. J Crohns Colitis, 2024, 18: i17-i18. doi: 10.1093/ecco-jcc/jjad212.0010
[4] Dubinsky MC, D'Haens G, Atreya R, et al. Op36 risankizumab versus ustekinumab for the achievement of clinical outcomes and symptom improvement in patients with moderate to severe crohn's disease: Results from the phase 3b sequence trial[J]. J Crohns Colitis, 2024, 18: i65-i66. doi: 10.1093/ecco-jcc/jjad212.0036
[5] Ferrante M, Panaccione R, Colombel JF, et al. Dop53 long-term efficacy and safety of risankizumab in patients with moderate to severe crohn's disease up to 3 years of treatment: Results from the fortify open-label long-term extension[J]. J Crohns Colitis, 2024, 18: i168-i170. doi: 10.1093/ecco-jcc/jjad212.0093
[6] Noor N, Lee J, Bond S, et al. Op01 profile: A multi-centre, randomised, open-label, biomarker-stratified clinical trial of treatment strategies for patients with newly-diagnosed crohn's disease[J]. J Crohns Colitis, 2024, 18: i1-i2. doi: 10.1093/ecco-jcc/jjad212.0001
[7] Van Der Does De Willebois E, Group Ss. Op19 extended mesenterectomy is not superior to mesenteric sparing resection in primary ileocolic resection for crohn's disease in terms of postoperative endoscopic recurrence-results of an international randomised controlled trial[J]. J Crohns Colitis, 2024, 18: i36. doi: 10.1093/ecco-jcc/jjad212.0019
[8] Trencheva K, Spinelli A, Kienle P, et al. Op20 postoperative endoscopic recurrence after resection of crohn's terminal ileitis with kono-s or side-to-side functional end anastomosis: Results of a multicenter prospective randomized trial[J]. J Crohns Colitis, 2024, 18: i37. doi: 10.1093/ecco-jcc/jjad212.0020
[9] Guedelha Sabino J. Op33 mechanistic insights on the role of ultra processed foods as a trigger/fuel for ibd[J]. J Crohns Colitis, 2024, 18: i59. doi: 10.1093/ecco-jcc/jjad212.0033
[10] Wong SY, Rowan C, Law CC, et al. Dop04 screening and management of fistula cancers in patients with perianal fistulising crohn's disease: An expert consensus[J]. J Crohns Colitis, 2024, 18: i77-i78. doi: 10.1093/ecco-jcc/jjad212.0044
[11] Guardiola Capón J, Iborra M, Padró A, et al. Op37 effect of the hla-dqa1*05 allele on the efficacy of ustekinumab in patients with crohn's disease. Multicenter study based on the eneida registry of geteccu[J]. J Crohns Colitis, 2024, 18: i67. doi: 10.1093/ecco-jcc/jjad212.0037
[12] Ben-Horin S, Lahat A, Ungar B, et al. Dop29 capsule endoscopy-guided proactive treatment versus standard treatment of patients with quiescent crohn's disease: The cure-cd randomized controlled trial[J]. J Crohns Colitis, 2024, 18: i125-i126. doi: 10.1093/ecco-jcc/jjad212.0069
[13] Rubín De Célix C, Ricart E, Martín-Arranz MD, et al. Dop75 frequency and effectiveness of dose escalation of biologic therapy in inflammatory bowel disease: The rainbow-ibd study of eneida[J]. J Crohns Colitis, 2024, 18: i211-i213. doi: 10.1093/ecco-jcc/jjad212.0115
-
计量
- 文章访问数: 509
- 施引文献: 0
下载: